Challenges and prospects of immunotherapy as cancer treatment Journal Article


Authors: Rescigno, M.; Avogadri, F.; Curigliano, G.
Article Title: Challenges and prospects of immunotherapy as cancer treatment
Abstract: The concept of cancer immunotherapy stems from the proposed function of the immune system, called immunosurveillance, to protect against growing tumors. Due to genetic aberrations, tumor cells display an altered repertoire of MHC-associated peptides that can lead to the activation of immune cells able to eliminate the transformed cells. In some instances, under the pressure of the immune system, both the tumor and its microenvironment are shaped and immune-resistant tumor variants are selected initiating the process of cancer immunoediting. This can impair not only host-generated immunosurveillance, but also attempts to harness the immune response for therapeutic purposes, namely immunotherapy. Rather than being an exhaustive review of the different approaches of cancer immunotherapy, the focus of this review is to provide the reader with future challenges of the field by proposing 'second generation' immunotherapy approaches that take into account immunosubversive mechanisms adopted by tumor cells. After an introduction on the process of immunosurveillance and immunoescape we will analyze why current immunotherapy approaches have not fulfilled their promise and will finish by summarizing what are the challenges for future approaches. © 2007 Elsevier B.V. All rights reserved.
Keywords: unclassified drug; clinical trial; review; bevacizumab; doxorubicin; fluorouracil; liver cell carcinoma; nonhuman; unspecified side effect; gemcitabine; pancreas cancer; ibritumomab tiuxetan; rituximab; neoplasms; colorectal cancer; animals; cytotoxic t lymphocyte antigen 4 antibody; dendritic cell vaccine; unindexed drug; cancer immunotherapy; melanoma; breast cancer; dendritic cell; lung non small cell cancer; cyclophosphamide; cetuximab; monoclonal antibodies; panitumumab; prostate cancer; regulatory t lymphocyte; nonhodgkin lymphoma; immunotherapy; antigens, neoplasm; cancer vaccine; drug mechanism; cancer vaccines; head and neck cancer; prophylaxis; uterine cervix cancer; cytotoxic t lymphocyte; acute myeloblastic leukemia; ovary carcinoma; tamoxifen; natural killer cell; taxane derivative; provenge; trastuzumab; granulocyte macrophage colony stimulating factor vaccine; immunosurveillance; chronic lymphatic leukemia; hepatitis b vaccine; tositumomab i 131; antigen presenting cell; antigen-presenting cells; alemtuzumab; gemtuzumab ozogamicin; tositumomab; wart virus vaccine; cancer immunoediting; immunologic surveillance; tumor escape; oncophage; trovax; tg 4010; harness; immunoevasion; epidermal growth factor receptor 2 vaccine; gv 1001; onyvax p; panvac cf; vectibix
Journal Title: Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Volume: 1776
Issue: 1
ISSN: 0304-419X
Publisher: Elsevier B.V.  
Date Published: 2007-09-01
Start Page: 108
End Page: 123
Language: English
DOI: 10.1016/j.bbcan.2007.07.003
PUBMED: 17720322
PROVIDER: scopus
DOI/URL:
Notes: --- - "Cited By (since 1996): 24" - "Export Date: 17 November 2011" - "CODEN: BBACE" - "Source: Scopus"
Altmetric Score
MSK Authors